Proactive Investors - Run By Investors For Investors

PDS Biotechnology shares pop on positive medical journal article

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells
Blood cells
The article explored how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) exploded Wednesday on news that an article supporting its signature cancer treatment platform will be published in the Journal of Immunology’s June issue.

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells, while making the cancer cells more vulnerable to attack.

The New Jersey company’s stock soared 43% to US$8.80.

The piece examines a preclinical study conducted at University of Kentucky School of Medicine, which corroborated the results of earlier preclinical studies regarding the immunological activity of PDS’ proprietary lipid molecule.

"As a cancer immunologist who has spent the last decade performing translational and clinical research in immuno-oncology at the National Cancer Institute, the versatility of PDS’ Versamune technology, and the strength of this recently published data, demonstrates Versamune’s potential to provide significant advancements in the treatment of various cancers and debilitating diseases,” said Chief Medical Officer Lauren Wood. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

clapperboard
March 04 2019
At the Completion Contract business there have been lower volumes and the average budget per film has reduced
pills
March 22 2019
The healthcare-focused advisory group boasts good levels of forward bookings thanks to several new business wins at the beginning of 2019
Augmented Reality on phone
March 21 2019
The firm currently has around nine companies in its portfolio that are either direct investments or through its sub-fund, Suir Valley Ventures, in which it holds a 22% stake
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use